Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis

Q Liu, C Qin, M Liu, J Liu - Infectious diseases of poverty, 2021 - mednexus.org
Background: To date, coronavirus disease 2019 (COVID-19) becomes increasingly fierce
due to the emergence of variants. Rapid herd immunity through vaccination is needed to …

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

WY Chi, YD Li, HC Huang, TEH Chan, SY Chow… - Journal of biomedical …, 2022 - Springer
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

[HTML][HTML] Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden

P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …

Efficacy and safety of the RBD-dimer–based COVID-19 vaccine ZF2001 in adults

L Dai, L Gao, L Tao, SR Hadinegoro… - New England journal …, 2022 - Mass Medical Soc
Background The ZF2001 vaccine, which contains a dimeric form of the receptor-binding
domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an …

Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico

LM Dunkle, KL Kotloff, CL Gay, G Áñez… - … England Journal of …, 2022 - Mass Medical Soc
Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle
vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease …

Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study

D Ayoubkhani, C Bermingham, KB Pouwels… - bmj, 2022 - bmj.com
Objective To estimate associations between covid-19 vaccination and long covid symptoms
in adults with SARS-CoV-2 infection before vaccination. Design Observational cohort study …

Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden

P Nordström, M Ballin, A Nordström - The Lancet Infectious Diseases, 2022 - thelancet.com
Background Real-world evidence supporting vaccination against COVID-19 in individuals
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

M Kumari, RM Lu, MC Li, JL Huang, FF Hsu… - Journal of biomedical …, 2022 - Springer
The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

COVID-19 and cellular senescence

CA Schmitt, T Tchkonia, LJ Niedernhofer… - Nature Reviews …, 2023 - nature.com
The clinical severity of coronavirus disease 2019 (COVID-19) is largely determined by host
factors. Recent advances point to cellular senescence, an ageing-related switch in cellular …